Knight Therapeutics announces launch for IMVEXXY in Canada

Knight Therapeutics (KHTRF) announced the launch of IMVEXXY in Canada. IMVEXXY is approved for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy. VVA is a prevalent, chronic, and progressive condition associated with menopause. Common symptoms of VVA include dryness, discomfort, and pain in the vaginal and vulvar areas. IMVEXXY is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose of 17beta estradiol; the 4 mcg represents the lowest effective Health Canada-approved dose of vaginal estradiol. Knight and TherapeuticsMD (TXMD) signed a license agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to IMVEXXY. Under the terms of the license agreement related to IMVEXXY in Canada, Knight will pay TherapeuticsMD sales milestone fees and royalties based upon certain aggregate annual sales of IMVEXXY in Canada.